

**Jubilant Life Sciences Limited**

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24116UP1978PLC004624

visit us at www.jubl.com

**Statement of Unaudited Standalone Results for the Quarter ended 30 June 2015**

(₹ in Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2015	2015	2014	2015
<b>PART I</b>					
<b>1</b>	<b>Income from operations</b>				
	(a) Net sales/Income from operations (Net of excise duty)	65685	71563	102601	314062
	(b) Other operating income	1228	863	1023	3568
	<b>Total Income from operations (net)</b>	<b>66913</b>	<b>72426</b>	<b>103624</b>	<b>317630</b>
<b>2</b>	<b>Expenses</b>				
	a) Cost of materials consumed	37110	32846	53034	166320
	b) Purchase of stock-in-trade	2934	7126	5633	19805
	c) Change in inventories of finished goods, work-in-progress and stock-in-trade	(3952)	5251	1032	7389
	d) Power and fuel expense	8551	7607	9253	32883
	e) Employee benefits expense	5270	5755	7970	24083
	f) Depreciation and amortization expense	2104	2268	4128	10741
	g) Other expenses	9659	9146	13244	39533
	<b>Total expenses</b>	<b>61676</b>	<b>69999</b>	<b>94294</b>	<b>300754</b>
<b>3</b>	<b>Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>5237</b>	<b>2427</b>	<b>9330</b>	<b>16876</b>
<b>4</b>	Other income	1307	2260	767	10642
<b>5</b>	<b>Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>6544</b>	<b>4687</b>	<b>10097</b>	<b>27518</b>
<b>6</b>	Finance costs (Refer note 2 below)	5767	4725	6314	22710
<b>7</b>	<b>Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>777</b>	<b>(38)</b>	<b>3783</b>	<b>4808</b>
<b>8</b>	Exceptional items (Refer note 3 below)	(527)	22053	(15294)	(19822)
<b>9</b>	<b>Profit/(Loss) from ordinary activities before tax (7-8)</b>	<b>1304</b>	<b>(22091)</b>	<b>19077</b>	<b>24630</b>
<b>10</b>	Tax expense (Net)	564	(1402)	(1295)	4119
<b>11</b>	<b>Net Profit/(Loss) from ordinary activities after tax (9-10)</b>	<b>740</b>	<b>(20689)</b>	<b>20372</b>	<b>20511</b>
<b>12</b>	Extraordinary items (net of tax expenses)	-	-	-	-
<b>13</b>	<b>Net Profit/(Loss) for the period (11-12)</b>	<b>740</b>	<b>(20689)</b>	<b>20372</b>	<b>20511</b>
<b>14</b>	Paid-up equity share capital (Face value per share ₹ 1)	1593	1593	1593	1593
<b>15</b>	Reserves (excluding revaluation reserve)				192903
<b>16</b>	Earnings per share of ₹ 1 each before and after extraordinary items (Not annualized)				
	Basic (₹)	0.46	(12.99)	12.79	12.88
	Diluted (₹)	0.46	(12.99)	12.79	12.88
<b>PART II</b>					
<b>A</b>	<b>PARTICULARS OF SHAREHOLDING</b>				
<b>1</b>	<b>Public shareholding</b>				
	- Number of shares (₹ 1 each)	73230083	73230083	73230083	73230083
	- Percentage of shareholding	45.98	45.98	45.98	45.98
<b>2</b>	<b>Promoters and promoter group shareholding</b>				
	<b>a) Pledged/Encumbered</b>				
	- Number of shares (₹ 1 each)	11137000	11137000	9700000	11137000
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	12.94	12.94	11.27	12.94
	- Percentage of shares (as a % of the total share capital of the Company)	6.99	6.99	6.09	6.99
	<b>b) Non-Encumbered</b>				
	- Number of shares (₹ 1 each)	74914056	74914056	76351056	74914056
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	87.06	87.06	88.73	87.06
	- Percentage of shares (as a % of the total share capital of the Company)	47.03	47.03	47.93	47.03
<b>B</b>	<b>Investor Complaints</b>				
	Pending at the beginning of the quarter	Nil			
	Received during the quarter	1			
	Disposed off during the quarter	Nil			
	Remaining unresolved at the end of the quarter	1			



# Jubilant Life Sciences Limited

Note 1: Unaudited Standalone Segment wise Revenue, Results and Capital Employed for the Quarter ended 30 June 2015

(₹ in Lacs)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June	31 March	30 June	31 March
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
		2015	2015	2014	2015
1	<b>Segment revenue</b>				
	a. Pharmaceuticals	573	108	20200	20971
	b. Life Sciences Ingredients	66340	72318	83516	296751
	<b>Total</b>	<b>66913</b>	<b>72426</b>	<b>103716</b>	<b>317722</b>
	Less : Inter segment revenue	-	-	92	92
	<b>Net Sales/Income from operations</b>	<b>66913</b>	<b>72426</b>	<b>103624</b>	<b>317630</b>
	a. Pharmaceuticals	573	108	20200	20971
	b. Life Sciences Ingredients	66340	72318	83424	296659
	<b>Total</b>	<b>66913</b>	<b>72426</b>	<b>103624</b>	<b>317630</b>
2	<b>Segment results (profit+)/loss(-) before tax, exceptional Items and Interest from each segment)</b>				
	a. Pharmaceuticals	(618)	(937)	1575	(975)
	b. Life Sciences Ingredients	8438	4411	10260	22968
	<b>Total</b>	<b>7820</b>	<b>3474</b>	<b>11835</b>	<b>21993</b>
	Less : i Interest (Finance costs)	5767	4725	6314	22710
	ii. Exceptional items and un-allocable expenditure	2288	22865	3719	28793
	iii. Exceptional items and un-allocable income	(1539)	(2025)	(17275)	(54140)
	<b>Total Profit/(Loss) before tax</b>	<b>1304</b>	<b>(22091)</b>	<b>19077</b>	<b>24630</b>
3	<b>Capital Employed (Segment assets less Segment liabilities)</b>				
	a. Pharmaceuticals	(140)	(425)	102947	(425)
	b. Life Sciences Ingredients	160713	155588	182354	155588
	<b>Total capital employed in segments</b>	<b>160573</b>	<b>155163</b>	<b>285301</b>	<b>155163</b>
	Add: Un-allocable corporate assets less liabilities (excluding deferred tax liabilities)	265064	282464	224595	282464
	<b>Total capital employed</b>	<b>425637</b>	<b>437627</b>	<b>509896</b>	<b>437627</b>



2. Finance costs include exchange difference arising from foreign currency short-term borrowings regarded as an adjustment to interest costs as per Accounting Standard (AS) 16 "Borrowing Costs", and is gross of credit on the swap contracts as under:

Particulars	(₹ in Lacs)			
	Quarter Ended			Year Ended
	30 June	31 March	30 June	31 March
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	2015	2015	2014	2015
Finance costs net of credit on swap contracts	5516	4105	4866	17448
Add: foreign exchange differences and credit on swap contracts	251	620	1448	5262
Gross finance costs	5767	4725	6314	22710

3. Exceptional items for each period presented include:

i) Amortization of debit balance in Foreign Currency Monetary Items Translation Difference Account (FCMITDA) of ₹ 790 lacs, ₹ 548 lacs, ₹ 2435 lacs and ₹ 4475 lacs for the quarters ended 30 June 2015, 31 March 2015, 30 June 2014; and year ended 31 March 2015; respectively, representing exchange difference on long-term foreign currency monetary liabilities which has been used for the purpose other than acquiring fixed assets.

ii) ₹ 18662 lacs and ₹ 5520 lacs representing write off of a loan (including interest accrued thereon) given to a subsidiary and net book value (adjusted for net realisable value) in respect of idle assets on usability assessment, respectively, recognised during the quarter and year ended 31 March 2015, profit on sale of investments amounting to ₹ 16508 lacs, profit on sale of businesses amounting to ₹ 27543 lacs to Jubilant Generics Limited, a step-down wholly owned subsidiary, recognised during the quarter ended 30 June 2014 and 30 September 2014 respectively and year ended 31 March 2015.

iii) The remaining amount of exceptional items, for all periods presented primarily represents foreign exchange difference for the period (excluding portion included in finance costs) and mark-to-market gain/ loss (net of related contractual recoveries) in respect of forward contracts, currency and interest rate swap contracts.

4. Previous periods figures have been reclassified to conform to the current period's classification. Further, the figures for the current period are not comparable to the previous periods due to transfer of certain businesses to Jubilant Generics Limited, a step-down wholly owned subsidiary with effect from 1 July 2014.

5. The above unaudited results were, subjected to limited review by the Statutory Auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11 August 2015. The figures for the preceding quarter ended 31 March 2015, as reported in these financial results, are the balancing figures between audited figures in respect of the full financial year ended 31 March 2015 and the published year to date unaudited figures upto the end of third quarter of the financial year. Also, the figures upto the end of the third quarter of the financial year were only reviewed and not subjected to audit. The review report of the Statutory Auditors is being filed with the Bombay Stock Exchange and National Stock Exchange and is also available on the Company's website at [www.jubl.com](http://www.jubl.com).

For Jubilant Life Sciences Limited

  
Hari S. Bhartia  
Co-Chairman & Managing Director

Place : Noida  
Date : 11 August 2015

